PPMD is pleased to learn of the U.S. commercial launch of AGAMREE® (vamorolone) oral suspension 40 mg/mL for the treatment of Duchenne in patients aged two years and older. According to Catalyst Pharmaceuticals, Inc., following the U.S. Food and Drug Administration (FDA) approval in October 2023, AGAMREE® is now available by prescription and dispensed throughout the United States through a specialty pharmacy network.

AGAMREE® aims to retain the beneficial anti-inflammatory and muscle-strengthening aspects of corticosteroids, while decreasing some of the undesirable side effects (bone fragility, delayed growth, insulin resistance, mood changes, delay of puberty and others).

To find out if you or your child is eligible to receive AGAMREE® and if your neuromuscular center is able to prescribe it, call your neuromuscular team, who will be able to provide you with the most appropriate information on next steps. If you have nonmedical questions about AGAMREE®, you can visit yourcatalystpathways.com or call 1-833-422-8259.

PPMD is thrilled to see another approved therapy for Duchenne become available to eligible individuals. You can find information about AGAMREE® on our Access & Coverage Resources page. We remain committed to working towards community access to all approved products and will continue to work with all relevant stakeholders to ensure a favorable access environment for our community.

Read Catalyst’s press release here.